Open AccessCell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study
Author(s) -
Christian Nußhag,
Christoph Rupp,
Felix C. F. Schmitt,
Ellen Krautkrämer,
Claudius Speer,
Florian Kälble,
Sandra Tamulyte,
Thomas Brückner,
Martin Zeier,
Jochen Reiser,
Markus A. Weigand,
Florian Uhle,
Uta Merle,
Christian Morath,
Thorsten Brenner
Publication year - 2019
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000004042
Subject(s) - medicine , acute kidney injury , renal replacement therapy , sepsis , plasminogen activator , urokinase , urokinase receptor , supar , prospective cohort study , urology , gastroenterology , intensive care medicine
Sepsis-induced acute kidney injury is the dominant acute kidney injury etiology in critically ill patients and is often associated with a need for renal replacement therapy. The indication and timing of renal replacement therapy are controversially discussed. We hypothesized that the product of the G1-cell cycle arrest biomarkers tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 ([TIMP-2] × [IGFBP7]), and the soluble urokinase-type plasminogen activator receptor are of diagnostic value for the prediction of septic acute kidney injury courses requiring renal replacement therapy.